Compare PRA & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRA | COLL |
|---|---|---|
| Founded | 1976 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2000 | 2015 |
| Metric | PRA | COLL |
|---|---|---|
| Price | $24.32 | $32.75 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $25.00 | ★ $51.40 |
| AVG Volume (30 Days) | ★ 705.7K | 500.6K |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.99 | ★ 1.73 |
| Revenue | ★ $1,098,028,000.00 | $780,567,000.00 |
| Revenue This Year | N/A | $8.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $24.43 | ★ $18.84 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $22.72 | $23.23 |
| 52 Week High | $24.85 | $50.79 |
| Indicator | PRA | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 40.86 | 32.91 |
| Support Level | $24.17 | $31.01 |
| Resistance Level | $24.41 | $32.92 |
| Average True Range (ATR) | 0.17 | 1.24 |
| MACD | -0.04 | 0.23 |
| Stochastic Oscillator | 29.05 | 23.67 |
ProAssurance Corp is a holding company for property and casualty insurance companies. The company's wholly-owned insurance subsidiaries provide professional liability insurance for healthcare professionals and facilities, professional liability insurance for attorneys, and workers' compensation insurance. ProAssurance reports operating results in five segments: Specialty Property and Casualty, Workers' Compensation, Segregated Portfolio Cell Reinsurance, Lloyd's Syndicate, and Corporate. ProAssurance generates the vast majority of its revenue from its Specialty P&C activities, followed by Worker's Compensation.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.